Optimizing the use of angiogenesis inhibitor in neovascular age-related macular degeneration

Optimizing the use of angiogenesis inhibitor in neovascular age-related macular degeneration

The purpose of the study was to estimate the effectiveness of using ranibizumab in combination with medotilin drug in the treatment of neovascular age-related macular degeneration (AMD). Material and methods. 50 patients (65 eyes) aged 41 to 88 (ave. 68.5 ± 0.98 years) with neovascular AMD were foll...

Full description

Bibliographic Details
Main Authors:	F. A. Bakhritdinova, A. F. Yusupov, Sh. A. Mukhanov
Format:	Article
Language:	Russian
Published:	Real Time Ltd 2018-10-01
Series:	Российский офтальмологический журнал
Subjects:	возрастная макулярная дегенерация хроническая неоваскуляризация ранибизумаб медотилин электроретинография age-related macular degeneration chronic neovascularization ranibizumab medotilin electroretinography
Online Access:	https://roj.igb.ru/jour/article/view/69

Similar Items

Early detection of choroidal neovascularization in age related macular degeneration
by: Tural Galbinur
Published: (2014-07-01)

The results of diagnostic and treatment of patients with diabetic retinopathy and age-related macular degeneration at a diabetes type 2.
by: I. V. Vorobyova, et al.
Published: (2014-10-01)

Assessment of effect of intravitreal ranibizumab injection on the ocular blood flow in patients with neovascular age-related macular degeneration
by: V. V. Neroev, et al.
Published: (2014-07-01)

Anti-VEGF therapy of neovascular age-related macular degeneration: from randomized trials to routine clinical practice
by: R. R. Fayzrakhmanov
Published: (2019-06-01)

Pathogenetic issues of retinal dystrophies associated with myopia and agerelated macular degeneration
by: I. B. Alekseev, et al.
Published: (2018-10-01)

Electrophysiological signs of retinal cone remodeling in geographic atrophy of the pigment epithelium in patients with non-exudative age-related macular degeneration
by: N. V. Neroeva, et al.
Published: (2021-09-01)

Myopia and age-related macular degeneration: structural and anatomical changes of the eye
by: I. B. Alekseev, et al.
Published: (2019-08-01)

Cataract surgery in patients with age-related macular degeneration: questions and controversies
by: E. I. Dmitrieva, et al.
Published: (2022-03-01)

Pharmacological Analysis of Resistance to Anti-VEGF Therapy
by: M. V. Budzinskaya, et al.
Published: (2019-01-01)

Efficacy and Safety of Nutraceutical Support in Age-Related Macular Degeneration Patients
by: S. V. Yanchenko, et al.
Published: (2023-01-01)

An Experimental and Clinical Justification for Prolongation of Action of Anti-VEGF Drug in the “Wet” Form Age-related Macular Degeneration by the Introduction in the Back Subtenon Space on the Basis of Viscous Media
by: R. V. Gaybaryan, et al.
Published: (2017-03-01)

Structural and Functional Criteria of Neuroprotection Effectiveness after Anti-VEGF Therapy in Patients with Neovascular Age-Related Macular Degeneration
by: N. S. Zhajvoronok, et al.
Published: (2019-12-01)

The Significance of Screening Questionnaire in the Evaluation of Age-Related Macular Risk Degeneration Development
by: L. A. Kochmasheva, et al.
Published: (2019-12-01)

Clinical Phenotypes of Patients with Neovascular Age-Related Macular Degeneration and Poor Response to Aflibercept Treatment
by: V. G. Likhvantseva, et al.
Published: (2022-10-01)

Polypoidal Choroidal Vasculopathy Treatment: Photodynamic Therapy, Anti-VEGF Monotherapy or Combination. Review of Clinical Studies
by: E. K. Pedanova, et al.
Published: (2019-06-01)

Pharmacoeconomic research of using aflibercept in patients with the wet age-related macular degeneration
by: S. V. Nedogoda, et al.
Published: (2020-03-01)

To the Question of Terminology, Expert Criteria for Evaluating the Effectiveness of Antiangiogenic Therapy and the Prevalence of Refractory Forms of Neovascular Age-Related Macular Degeneration. Review
by: V. G. Likhvantseva, et al.
Published: (2021-10-01)

Experience with Brolucizumab Treatment of Neovascular Age-Related Macular Degeneration
by: M. V. Budzinskaya, et al.
Published: (2023-01-01)

The role of free-radical processes in the pathogenesis of age-related macular degeneration. Review
by: A. V. Kolesnikov, et al.
Published: (2014-07-01)

Long-Term Outcomes of Nonadherence to Anti-VEGF Therapy in Advanced Neovascular Age-Related Macular Degeneration
by: A. N. Kulikov, et al.
Published: (2022-10-01)

An integrated analysis of clinical and morphometric indications of atrophic forms of age-related macular degeneration
by: N. V. Neroeva, et al.
Published: (2022-01-01)

The complex model of risk and progression of AMD estimation
by: V. S. Akopyan, et al.
Published: (2014-07-01)

The Use of Nutraceuticals in Patients with “Dry” Form of Age-Related Macular Degeneration on the Background of Accelerated Aging
by: S. A. Korotkih, et al.
Published: (2019-06-01)

Efficiency of Retinoprotective Dry AMD Therapy with Neuroprotective Therapy: a Randomized Clinical Trials Meta-analysis
by: V. P. Erichev, et al.
Published: (2018-03-01)

Mixed (combined) phenotype of the late stage of age-related macular degeneration
by: N. V. Neroeva, et al.
Published: (2021-06-01)

Treatment of macular diseases: an overview of key randomized clinical trials
by: E. V. Bobykin, et al.
Published: (2022-01-01)

Epidemiology of Age-Related Macular Degeneration in the Republic of Bashkortostan (Clinical and Statistical Analisys of the “Ural Eye and Medical Study”)
by: T. R. Gilmanshin
Published: (2019-04-01)

Our Experience of Nutraceutical Effects in Age-Related Macular Degeneration
by: S. V. Yanchenko, et al.
Published: (2020-12-01)

Experiences of treatment of age related macular degeneration with concomitant myopia
by: I. B. Alekseev, et al.
Published: (2019-03-01)

Efficacy of the drug Vitalux Plus of patients with dry form of age-related macular degeneration
by: I. R. Gazizova, et al.
Published: (2014-07-01)

Study of the Level of Pro- and Antiangiogenic Growth Factors in Vitreous Fluid in Neovascular Age-Related Macular Degeneration on the Background of Treatment
by: M. M. Arkhipova, et al.
Published: (2022-07-01)

An integrated assessment of ophthalmogeriatric changes in patients with the wet form of agerelated macular degeneration
by: A. Y. Brezhnev, et al.
Published: (2022-06-01)

Functional express testing and self monitoring in the diagnosis and treatment of macular diseases
by: S. O. Milyutkina, et al.
Published: (2018-10-01)

Non-Invasive Diagnosis of Polypoidal Choroidal Vasculopathy as a Variant of the Course of Age-Related Macular Degeneration
by: I. E. Panova, et al.
Published: (2018-07-01)

Principles of anti-VEGF dosing in the treatment of neovascular age-related macular degeneration
by: I. E. Ioshin, et al.
Published: (2019-08-01)

The Effectiveness of Retinalamin® Administered by Various Intramuscular Injection Timings in the Treatment of Patients with the Dry Form of Age- Related Macular Degeneration
by: V. V. Neroev, et al.
Published: (2018-10-01)

Evaluation of Flowmetry Indicators in Patients with a Wet AMD Form during Antiangiogenic Therapy
by: N. Yu. Yousef, et al.
Published: (2019-12-01)

Nutraceuticals for Age-Related Macular Degeneration: Formulation Optimization Focused on Safety
by: E. K. Pedanova
Published: (2022-04-01)

ADVANCED MEDICAL INFORMATION TECHNOLOGY 1.0 PROGRAM APPLICATION IN THE ANALYSIS OF PATIENTS WITH THE AGE-RELATED MACULAR DEGENERATION
by: Ye. V. Melehin, et al.
Published: (2014-02-01)

Retinal clinical and morphofunctional changes in high myopia in combination with age-related macular degeneration of different stages
by: L. K. Moshetova, et al.
Published: (2022-09-01)